|
|
||||||||
1 Cardiovascular Division,
Endothelin (ET)-1 has potent positive inotropic and chronotropic activity in the heart and induces cardiac hypertrophy. The production of ET-1 in the heart is reported to be increased under some conditions. In normal circulation, the pressure load to the left ventricle (LV) is much greater than that to the right ventricle (RV). In this study, we investigated the gene expression of the myocardial ET-1 system (ET-1, ETA receptor, and ETB receptor) in the RV and LV of normal rats and also investigated these genes in hypertrophied RV due to pathological pulmonary hypertension (PH). Normal rats showed no differences between the RV and LV in the gene expression of either ET-1, ETA receptor, or ETB receptor in either the adult stage (11 wk old) or the neonatal stage (1 and 8 days old). On the other hand, the expression of both atrial natriuretic peptide (ANP) mRNA and B-type natriuretic peptide (BNP) mRNA was significantly greater in the LV than in the RV in adult rats. Gene expression of ET-1, ETA receptor, and ETB receptor in the RV was markedly higher in rats with monocrotaline-induced (pathological) PH than that in control rats. The expression of ANP mRNA and BNP mRNA in the RV was also markedly higher in the rats with PH. In conclusion, the data suggest that gene expression of the ET-1 system in the myocardium is not affected by physiological pressure load in either the adult stage or neonatal stage; however, it is enhanced by pathological pressure overload such as that in PH.
myocardial endothelin-1 system; pressure overload; pulmonary hypertension; cardiac hypertrophy; atrial natriuretic peptide; B-type natriuretic peptide
This article has been cited by other articles:
![]() |
K. T. B. Mouchaers, I. Schalij, A. M. G. Versteilen, A. M. Hadi, G. P. van Nieuw Amerongen, V. W. M. van Hinsbergh, P. E. Postmus, W. J. van der Laarse, and A. Vonk-Noordegraaf Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H200 - H207. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iemitsu, T. Miyauchi, S. Maeda, S. Sakai, T. Kobayashi, N. Fujii, H. Miyazaki, M. Matsuda, and I. Yamaguchi Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R2029 - R2036. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, X. T. Gan, J. V. Haist, Q. Feng, X. Lu, S. Chakrabarti, and M. Karmazyn Attenuation of Compensatory Right Ventricular Hypertrophy and Heart Failure following Monocrotaline-Induced Pulmonary Vascular Injury by the Na+-H+ Exchange Inhibitor Cariporide J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 469 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Torre-Amione, J. B. Young, J.-B. Durand, B. Bozkurt, D. L. Mann, I. Kobrin, and C. M. Pratt Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure Circulation, February 20, 2001; 103(7): 973 - 980. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |